| Literature DB >> 32351918 |
Ti-Long Huang1, Tian-Yao Zhang2, Chun-Yan Song1, Yun-Bi Lin1, Bao-Hua Sang1, Qing-Ling Lei1, Yu Lv1, Chun-Hui Yang1, Na Li1, Xin Tian1, Yue-Huang Yang1, Xian-Wen Zhang3.
Abstract
Background: Thalassemia is an autosomal genetic disorder, found throughout the world. It is still not treatable and create socio economic problems. In this study, we investigated the prevalence and spectrum features of thalassemia in Yunnan Province, the southwestern area of China. During 2014-2018, a total of 3,539 suspected thalassemia children were detected with α- and β-thalassemia mutations by gap-Polymerase Chain Reaction (PCR) and reverse dot blot (RDB) analysis in Kunming Children's Hospital.Entities:
Keywords: China; Yunnan province; children; gene mutation spectrum; thalassemia
Year: 2020 PMID: 32351918 PMCID: PMC7174584 DOI: 10.3389/fped.2020.00159
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.418
Frequency of α-thalassemia mutations in children in the Yunnan province.
| Heterozygote | 402 | 81.54 | |
| –SEA/αα | α0/α | 257 | 52.13 |
| –α3.7/αα | α+/α | 137 | 27.79 |
| –α4.2/αα | α+/α | 8 | 1.62 |
| Compound heterozygote | 91 | 18.46 | |
| –SEA/–α3.7 | α0/α+ | 81 | 16.43 |
| –SEA/–α4.2 | α0/α+ | 10 | 2.03 |
| Total | 493 | 100 |
α, normal production of the α-globin polypeptide chain; α.
Distribution of carriers of both α- and β-thalassemia genotypes in children in Yunnan province.
| –SEA/αα, CD17/βN | α0/α | β0/βN | 4 | 14.81 |
| –SEA/–α3.7, CD26/βN | α0/α+ | βE/βN | 4 | 14.81 |
| –α3.7/αα, CD17/βN | α+/α | β0/βN | 3 | 11.11 |
| –SEA/αα, CD41–42/βN | α0/α | β0/βN | 3 | 11.11 |
| –SEA/αα, CD26/βN | α0/α | βE/βN | 2 | 7.41 |
| –α3.7/αα, CD41–42/βN | α+/α | β0/βN | 2 | 7.41 |
| –α4.2/αα, CD41–42/CD17 | α+/α | β0/β0 | 1 | 3.70 |
| –SEA/–α3.7, CD17/βN | α0/α+ | β0/βN | 1 | 3.70 |
| –SEA/αα, CD41–42/CD17 | α0/α | β0/β0 | 1 | 3.70 |
| –SEA/αα, CD43/IVS-II-654 | α0/α | β0/β0 | 1 | 3.70 |
| –SEA/–α4.2, CD41–42/βN | α0/α+ | β0/βN | 1 | 3.70 |
| –α3.7/αα, CD17/−28 | α+/α | β0/β+ | 1 | 3.70 |
| –α3.7/αα, CD41–42/CD17 | α+/α | β0/β0 | 1 | 3.70 |
| –α3.7/αα, IVS-II-654/βN | α+/α | β0/βN | 1 | 3.70 |
| –α3.7/αα, CD26/βN | α+/α | βE/βN | 1 | 3.70 |
| Total | 27 | 100.00 | ||
α, normal production of the α-globin polypeptide chain; α.
Frequency of β-thalassemia mutations in children in the Yunnan province.
| Heterozygote | 508 | 83.29 | |
| CD17/βN | β0/βN | 180 | 29.51 |
| CD41–42/βN | β0/βN | 170 | 27.87 |
| IVS-II-654/βN | β0/βN | 91 | 14.92 |
| CD26/βN | βE/βN | 42 | 6.89 |
| CD71–72/βN | β0/βN | 15 | 2.46 |
| IVS-I-I/βN | β0/βN | 4 | 0.66 |
| −28/βN | β+/βN | 3 | 0.49 |
| −29/βN | β+/βN | 1 | 0.16 |
| CD34/βN | 1 | 0.16 | |
| CD43/βN | β0/βN | 1 | 0.16 |
| Compound heterozygote | 82 | 13.44 | |
| CD26/CD27 | βE/β0 | 16 | 2.62 |
| CD41–42/CD17 | β0/β0 | 15 | 2.46 |
| CD26/IVS-II-654 | βE/β+ | 11 | 1.80 |
| CD41–42/CD26 | β0/βE | 10 | 1.64 |
| CD17/−28 | β0/β+ | 5 | 0.82 |
| CD27/CD28 | β0/β0 | 4 | 0.66 |
| CD17/IVS-II-654 | β0/β+ | 4 | 0.66 |
| CD41–42/IVS-II-654 | β0/β0 | 3 | 0.49 |
| CD41–42/CD43 | β0/β0 | 3 | 0.49 |
| CD41–42/−28 | β0/β+ | 3 | 0.49 |
| CD14–15/βN | β0/βN | 3 | 0.49 |
| CD26/−28 | βE/β+ | 1 | 0.16 |
| CD26/CD43 | βE/β0 | 1 | 0.16 |
| CD71–72/CD26 | β0/βE | 1 | 0.16 |
| CD41–42/IVS-I-I | β0/β0 | 1 | 0.16 |
| INT/βN | β0/βN | 1 | 0.16 |
| Homozygote | 20 | 3.29 | |
| CD17/CD17 | β0/β0 | 13 | 2.13 |
| CD41–42/CD41–42 | β0/β0 | 4 | 0.66 |
| IVS-II-654/IVS-II-654 | β0/β0 | 2 | 0.33 |
| CD26/CD26 | βE/βE | 1 | 0.16 |
| Total | 610 | 100 |
β.